Construction of a versatile fusion protein for targeted therapy and immunotherapy
Protein Science · 2024
DOI: 10.1002/pro.4944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, 2024. Verfasst von Xiu-Song Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinicopathological Diagnosis & Research Center, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China. Hauptthemen laut MEDLINE: Neoplasms, Cell-Penetrating Peptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program, Science and Technology Commission of Pudong New Area Foundation.
Abstract (Originalsprache)
Antibody (Ab)‐based drugs have been widely used in targeted therapies and immunotherapies, leading to significant improvements in tumor therapy. However, the failure of Ab therapy due to the loss of target antigens or Ab modifications that affect its function limits its application. In this study, we expanded the application of antibodies (Abs) by constructing a fusion protein as a versatile tool for Ab‐based target cell detection, delivery, and therapy. We first constructed a SpaC Catcher (SpaCC for short) fusion protein that included the C domains of Staphylococcal protein A (SpaC) and the SpyCatcher. SpaCC conjugated with SpyTag‐X (S‐X) to form the SpaCC‐S‐X complex, which binds non‐covalently to an Ab to form the Ab‐SpaCC‐S‐X protein complex. The “X” can be a variety of small molecules such as fluoresceins, cell‐penetrating peptide TAT, Monomethyl auristatin E (MMAE), and DNA. We found that Ab‐SpaCC‐S‐FITC(−TAT) could be used for target cell detection and delivery. Besides, we synthesized the Ab‐SpaCC‐SN3‐MMAE complex by linking Ab with MMAE by SpaCC, which improved the cytotoxicity of small molecule toxins. Moreover, we constructed an Ab‐DNA complex by conjugating SpaCC with the aptamer (Ap) and found that Ab‐SpaCC‐SN3‐Ap boosted the tumor‐killing function of T‐cells by retargeting tumor cells. Thus, we developed a multifunctional tool that could be used for targeted therapies and immunotherapies, providing a cheap and convenient novel drug development strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinicopathological Diagnosis & Research Center, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
- Key Laboratory of Tumor Molecular Pathology of Guangxi Higher Education Institutes, Baise, China.
- Graduate School of Youjiang Medical University for Nationalities, Baise, China.
- Key Laboratory of Pediatric Hematology and Oncology Ministry of Health and Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shan…
- Fujian Branch of Shanghai Children's Medical Center Affiliated to SJTU-SM, and Fujian Children's Hospital, Fujian, China.
- Nanchong Second People's Hospital, Nanchong, China.
ORCID-Profile: Cai-Wen Duan
Förderung
- National Natural Science Foundation of China
- Shanghai Sailing Program
- Science and Technology Commission of Pudong New Area Foundation
- Guangxi Natural Science Foundation Program
- Key Laboratory of Tumor Molecular Pathology of Guangxi Higher Education Institutes (Guijiaokeyan [2022]-10)
Zitieren
APA
Huang, X. S., Yang, L. T., Yang, K., Zhou, H., Abudureheman, T., Zheng, W. W., Chen, K. M., & Duan, C. W. (2024). Construction of a versatile fusion protein for targeted therapy and immunotherapy. Protein Science. https://doi.org/10.1002/pro.4944
Vancouver
Huang XS, Yang LT, Yang K, Zhou H, Abudureheman T, Zheng WW, et al. Construction of a versatile fusion protein for targeted therapy and immunotherapy. Protein Science. 2024. doi:10.1002/pro.4944
BibTeX
@article{Huang2024,
author = {Huang, Xiu-Song and Yang, Li-Ting and Yang, Ke and Zhou, Hang and Abudureheman, Tuersunayi and Zheng, Wei-Wei and Chen, Kai-Ming and Duan, Cai-Wen},
title = {Construction of a versatile fusion protein for targeted therapy and immunotherapy},
journal = {Protein Science},
year = {2024},
doi = {10.1002/pro.4944}
}
EUVIMED